Treatment and rehabilitation of Long COVID: a scope of the literature.: Update October 2022

Gary Austin Raine; Claire Louise Khouja; Melissa Harden; Katy Sutcliffe; Amanda Jayne Sowden

Treatment and rehabilitation of Long COVID: a scope of the literature. Update October 2022

Gary Austin Raine, Claire Louise Khouja, Melissa Harden, Katy Sutcliffe, Amanda Jayne Sowden

Centre for Reviews and Dissemination

Research output: Book/Report › Commissioned report

Abstract

Summary
• We identified 11 randomised controlled trials published since June 2022 that were focused on Long COVID treatment or rehabilitation. Across two reports, we have now identified and assessed 25 trials published in 2022.
• A majority of trials focused on evaluating treatments for people with persistent problems with their sense of smell (olfactory dysfunction).
• Trial quality varied and inadequate reporting of methods often prevented a full assessment of the risk of bias. However, six trials were rated positively for at least 11 out of the 13 criteria that we assessed.

Original language	English
Place of Publication	London
Publisher	EPPI-Centre, Social Science Research Unit, UCL Institute of Education, University College London.
Commissioning body	NIHR Policy Research Programme
Number of pages	22
ISBN (Electronic)	978-1-911605-37-9
Publication status	Published - Oct 2022

Access to Document

LC_treatment2_oct_final_LO071122
Authors of the systematic reviews on the EPPI Centre website (http://eppi.ioe.ac.uk/) hold the copyright for the text of their reviews. The EPPI Centre owns the copyright for all material on the website it has developed, including the contents of the databases, manuals, and keywording and data-extraction systems. The centre and authors give permission for users of the site to display and print the contents of the site for their own non-commercial use, providing that the materials are not modified, copyright and other proprietary notices contained in the materials are retained, and the source of the material is cited clearly following the citation details provided. Otherwise users are not permitted to duplicate, reproduce, re-publish, distribute, or store material from this website without express written permission.
Final published version, 2.85 MBLicence: CC BY-NC

Cite this

@book{f02641a348a14851ac95a13540cf6a80,

title = "Treatment and rehabilitation of Long COVID: a scope of the literature.: Update October 2022",

abstract = "Summary• We identified 11 randomised controlled trials published since June 2022 that were focused on Long COVID treatment or rehabilitation. Across two reports, we have now identified and assessed 25 trials published in 2022.• A majority of trials focused on evaluating treatments for people with persistent problems with their sense of smell (olfactory dysfunction).• Trial quality varied and inadequate reporting of methods often prevented a full assessment of the risk of bias. However, six trials were rated positively for at least 11 out of the 13 criteria that we assessed.",

author = "Raine, {Gary Austin} and Khouja, {Claire Louise} and Melissa Harden and Katy Sutcliffe and Sowden, {Amanda Jayne}",

year = "2022",

month = oct,

language = "English",

publisher = "EPPI-Centre, Social Science Research Unit, UCL Institute of Education, University College London.",

}

TY - BOOK

T1 - Treatment and rehabilitation of Long COVID: a scope of the literature.

T2 - Update October 2022

AU - Raine, Gary Austin

AU - Khouja, Claire Louise

AU - Harden, Melissa

AU - Sutcliffe, Katy

AU - Sowden, Amanda Jayne

PY - 2022/10

Y1 - 2022/10

N2 - Summary• We identified 11 randomised controlled trials published since June 2022 that were focused on Long COVID treatment or rehabilitation. Across two reports, we have now identified and assessed 25 trials published in 2022.• A majority of trials focused on evaluating treatments for people with persistent problems with their sense of smell (olfactory dysfunction).• Trial quality varied and inadequate reporting of methods often prevented a full assessment of the risk of bias. However, six trials were rated positively for at least 11 out of the 13 criteria that we assessed.

AB - Summary• We identified 11 randomised controlled trials published since June 2022 that were focused on Long COVID treatment or rehabilitation. Across two reports, we have now identified and assessed 25 trials published in 2022.• A majority of trials focused on evaluating treatments for people with persistent problems with their sense of smell (olfactory dysfunction).• Trial quality varied and inadequate reporting of methods often prevented a full assessment of the risk of bias. However, six trials were rated positively for at least 11 out of the 13 criteria that we assessed.

M3 - Commissioned report

BT - Treatment and rehabilitation of Long COVID: a scope of the literature.

PB - EPPI-Centre, Social Science Research Unit, UCL Institute of Education, University College London.

CY - London

ER -